Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
More/recap on DNAPrint Pharmaceuticals:
http://www.sys-con.com/read/256408.htm
Ann
" maybe someone out there with better connections could notify the press...."
Jever:
I don't think DNAG would want their participation in such a high profile case revealed at any cost at this current time, since it could damage the credibility and issues as applied to the case in court, (if it ever turns out to be a hard case). Remember, they haven't proved Kerr to be credible on his confessions yet. But, if he turns out to be, in fact, the real killer, we need to have this case played out according to the professionalism it must. If it's DNAP doing the DNA testing, they will inform us "when the time is right". (If that EVEN EVER happens if would certainly be a large feather in DNAP's our our caps!)
JMHO
Ann
usmc:
I wonder who's doing the trading? I believe that you are not allowed to trade (buy/sell) the pink sheet stocks after hrs.
Someone correct if I'm wrong.
Ann
usmc:
"Why such single huge transaction after hours?
Just curious."
This happened yesterday and frequently. I am curious also. Perhaps someone can clue us in.
Take care,
Ann
That was my point also, Chiggah.
Take care,
Ann
Ebo:
You may be right.
Ann
Re: Karr and JonBennet case
Am listening to FOX news right now.
He has already been given a DNA test in Thailand and upon his arrival in US - (probably within a couple of days), he will be given another DNA testing. Wouldn't it be appropriate and I hope they use "DNA Witness?" - perfectly suited for this case, at this time. Just MHO
(I do recall seeing a special or someone quoting that the Mother wanted DNAP to perform DNA testing early in the case, but that the Denver Police had botched up many aspects of the case).
Ann
Posted by: cosmiclifeform
In reply to: IVRT who wrote msg# 11701 Date:1/28/2004 1:36:43 PM
Post #of 49749
IVRT - There have been 4 formal PR announcements of DNAPrint Genomics helping with investigations so far...
1) Derrick Lee - Louisana Serial Killer Case - Baton Rouge, LA - May 2003
2) Trailside Murder Case - Concord, Calif. - Aug 2003
3) Woman Found Dead Was Dismembered - Winchester Star, VA - Dec 30, 2003
4) DNA Offers Clue In Susannah Chase Killing : Boulder News - January 21, 2004
And one that is a hot potato nationally - DNAPrint Genomics was clearly mentioned as actively involved with the JonBenet Ramsey case as well.... This one could be a firecracker...
Also Tony stated they are currently working on over 30 other cases right now...the growing number of cases are quite encouraging if not exciting...!
Appears DNA Witness is getting lots of attention and validation and with more and more cases, revenues will be building from here... Great start! Soon DNA Witness will be mainstream...the market leader and the new standard for forensics.
The market for forensics is huge...internationally as well...!
Ming offered a nice estimation that used national data showing even 1% of the market is over $144 million a year... If we extend this formula to the world market....Whew! Revenues galore...and from just ONE product...DNA Witness!"
Ann
A portion of DNA WITNESS case release: (6/06)
"DNAWitness™ Used to Guide the Investigation of the '97 rape and murder of Susannah Chase
DNAPrint genomics (OTCBB: DNAP) of Sarasota, FL confirmed that its DNAWitness™ test was strategically employed in an investigation by the Boulder, Colorado Police Department.
Susannah Chase, 23 was brutally beaten and raped in December of 1997. Her body, as well as a DNA specimen, was found several days later.
A representative of the Boulder Police Department has stated, "DNAPrint reported that the DNA investigators submitted is indicative of someone exhibiting features that are common to Hispanics or Native Americans. This information will assist detectives with prioritizing tips and possibly generate more investigative leads."
DNA is commonly left at crime scenes, but until DNAPrint™ developed DNAWitness™, no ancestral or physical information could be reliably read from that DNA (other than gender). The genetic heritage of an individual cannot be accurately inferred from standard DNA tests. DNAWitness™ is powered by 175 of the human genome's best Ancestry Informative Markers (AIMs) and measures an individual's ancestry admixture from his or her DNA. From simulations and direct observations, it is known that DNAWitness results are precise to within a few percent, depending on the type of admixture present.
Standard DNA testing provides a unique identifier from the crime scene DNA, but in this case, the crime scene DNA did not match any of the profiles in the FBI's CODIS database, making the identification of the suspect impossible at this time. Detectives continued their quest to learn about the donor of the DNA at the crime scene and their search led investigators to DNAPrint genomics™, which is the first and so far only company able to offer this new type of DNA analysis. The test was applied by investigators to infer physical information about the suspect from the crime scene DNA, allowing them to focus precious investigative resources on high value leads related to the crime.
Forensic validation studies of DNAWitness™ have been performed by the San Diego Police Department Crime Lab, the National Center for Forensic Science and the Broward County Crime Lab. In July, 2003, a report in the Journal of Forensic Science provided the scientific rationale and results of studies related to DNAWitness™, and the test has since been covered by Popular Science, US News and World Report, the New York Times, and national ABC and CBS news programs. DNAPrint genomics ™ has successfully determined the ancestral background of over 5,000 individuals."
Ann
Posted on RB by Billycal:
Here is a part of a correspondence between myself and someone who is familiar with FDA/Govt. proceedures.
Bill,
..."DNAG is in the process of developing a biological drug product that is in a class of products called "super-EPO". EPO is the acronym for erythropoeitin, a biological drug that aids in the transport of oxygen in the blood. It is used to support patients who are receiving chemotherapy who have developed low red blood cell counts and for other medical uses (also used by athletes in a "doping" way to increase their blood oxygen content which gives a competitive advantage). Super-EPO is a far more potent version of the old EPO and I believe that a number of companies, including DNAG have some sort of super-EPO in development. According to the press releases, DNAG is making consistent forward progress in developing its super-EPO, which has potentially a huge market once approved. DNAG has set up a relationship with a separate (wholly owned?) company to manufacture the product according to "good manufacturing practices" (GMPs) which is required by the FDA. One of the early steps in eventually securing a new drug approval (NDA) is demonstrating to the FDA that the company can produce the product with reliable potency and free of contamination (a particular concern with biological products). DNAG has done this already or at least demonstrated the contaminants-free bit. DNAG also is working with Beth Israel Deaconness to perform some of the pre-clinical (i.e. lab or animal model) tests on the product. The data from these studies, along with compliance with GMPs, will eventually be submitted to the FDA to request an investigational new drug (IND) license. Then the company can begin the three-stage clinical trial process to test the product in humans. From the press releases, and this is only a guess, it looks like the company might be positioned to request an IND in 12 to 18 months. I don't know how long the FDA takes these days to review and grant an IND request, but it would probably be multiple months, perhaps longer. The clinical trials phases I, II, and III can take multiple years depending on how many people are enrolled and how complicated the study design is and what the company thinks the FDA will want in terms of human data. They will have to test for safety, determine appropriate dosing, and of course test for efficacy. This is also a guess, but it would appear that, even if everything goes well, the company is still several years away from bringing the super-EPO product to market (but this is typical for new drug development). They do seem to be making good progress and the partnership with Beth Israel Deaconness (and Harvard Medical School) certainly suggests that people who really know about this product have some confidence in it. Let me know if you have any questions."
Ann
Dorsey:
OT:
"Maybe someone at google got it in for Mr. Bush......"
MAYBE? - lol - on with the day and you have a good one.
Ann
66:
We'll just have to follow the story.
Take care,
Ann
That's sad, IMHO
Ann
66:
Part of the story that broke today:
"BANGKOK, Thailand (Aug. 17) - An American suspect arrested in connection with the death of 6-year-old beauty queen JonBenet Ramsey denied any connection to her murder when he was detained at his downtown Bangkok apartment Wednesday, police said.
The suspect was identified as John Mark Karr, according to Lt. Gen. Suwat Tumrongsiskul, who heads the country's immigration police. He was arrested at the request of U.S. officials following an investigation in Thailand, although police said he had not committed any crime in that country.
Federal officials in the U.S., speaking on condition of anonymity, also identified the suspect as Karr, a 41-year-old American, and said he was being held in Bangkok on unrelated sex charges."
It should be interesting, as it unravels...
Ann
66:
"Hmmmm Asian????"
His name does not imply that he's Asian. However, I'm not sure exactly what you are trying to state in your comments.
Ann
usmc
" think they said it was President George Bush's fault for the murder."
Next thing you know, they'll blame George Bush for DNAG's price manipulation - lol
Ann
Glenda:
I'm listening to the same Ramsey coverage on Fox News right now.
Take care,
Ann
DNAWITNESS User Manual:
http://dnaprint.humid.e-symposium.com/dnawitness/um.html
Have a good one, all
Ann
DNAWITNESS Web Page:
http://dnaprint.humid.e-symposium.com/dnawitness/validation.html
Ann
More on DNA Witness:
"The kit puts the power of DNAPrint's forensics technology directly into the hands of local crime scene investigators," stated Zach Gaskin, DNAPrint's Technical Coordinator of Forensics. "It also is a valuable time- and cost- saving investigative tool because it reduces the number of false leads that detectives normally would have to chase. In addition, many forensics laboratories want to keep control of their crime scene samples in order to maintain a chain of custody for evidence in order to reduce challenges in court."
The kit is the first of its kind developed for the consumable test kit market and contains all of the reagents and protocols required for forensics laboratories around the world to perform their own ancestry analysis. Proprietary on-line software systems provided by DNAPrint(TM) are expected to enable investigators to interpret their results and relate them to the likely anthropometric (physical) features of a would-be suspect by referencing DNA samples to DNAPrint's proprietary ancestry databases.
The DNAWitness(TM) kit can be utilized on capillary electrophoresis (CE) instruments commonly found in forensic and university laboratories. Starting this week, the kit will be entering beta testing at select forensics laboratories. After the testing phase, which is expected to take three to four months, the Company intends to build an inventory of kits for its distributor network and its own sales force for sale to the forensics market. The Company's testing services are available for the screening of a large number of samples or individual samples, until and even after the kit is available; investigators, forensic scientists and medical examiners need not wait until the kit is available to access this powerful new technology.
Ann
From today's AOL News on Gene mapping:
Researchers Begin Gene Mapping Project
By MIKE STOBBE
AP
ATLANTA (Aug. 10) - Atlanta-based researchers say they've begun mining a new kind of genetic data in a project that may help explain why some people are susceptible or resistant to certain diseases.
A summary of the work by Emory University researchers was released Thursday. It's being published in a scientific journal, Genome Research.
"The topic is quite exciting" and the Emory researchers are breaking new ground, said Lisa Brooks of the National Human Genome Research Institute, a federal agency. She is director of the Institute's genetic variation program.
Scientists think that in as soon as 10 years, doctors will be able to examine the DNA of newborn babies and compare it to a reference code of human DNA to make predictions about each infant's susceptibility to disease. Such information could help doctors know which medicines will work most effectively on that person if illness develops.
"We're entering an exciting new era of predictive health," said Scott Devine, an Emory assistant professor of biochemistry who co-authored the paper.
The Emory work should contribute to that, he added.
In 2000, scientists announced they had substantially finished mapping the genetic blueprint for all human cells. The breakthrough was heralded as ushering in a new era of medicine, which would -- and to some extent has -- led to new ways to test for and treat disease.
The finished human genome sequence was published in 2003, and was based on DNA from about a half-dozen people.
The mapping showed the human genome is built from billions of chemical building blocks that appear in pairs. The blocks come in four types: adenine (A), thymine (T) cystosine (C) and guanine (G).
Since then, scientists have been focused on mapping tiny variations in the genetic code of 36 additional people, in an attempt to understand why, for example, some nonsmokers develop lung cancer while some lifelong smokers never get sick.
The variations are called "snips" -- or SNPs -- an abbreviation for "single-nucleotide polymorphisms." They involve single-block replacements. That is, part of one person's genetic sequence might read A-T-C, but a SNP might replace a G for the C in the next person, resulting in A-T-G.
A federally led mapping of the SNP variations was published last year.
In the new work, Emory researchers used the SNP mappers' data, but applied a new kind of computer-based analysis to look for another type of variation called an INDEL -- for insertion and deletion polymorphism.
In an INDEL, building blocks are added or deleted, not just switched on a one-for-one basis. And an insertion or deletion can involve thousands of blocks.
INDELs represent as much as 25 percent of all genetic variations, Emory researchers said. They already have been shown to be the cause of several genetic diseases, including cystic fibrosis, Devine said.
Ann
Those who have not read the news release:
http://www.marketwire.com/mw/release_html_b1?release_id=109692
Ann
Super EPO progress:
"DNAPrint Pharmaceuticals Completes Development, Validation On Second Assay For Investigational Anemia Drug
8/7/2006
Source: VerusMed
KBI BioPharma Inc. has completed and validated a second analytical method for PT-401, an anemia drug. The method is based on SDS-PAGE, a well-established separation technique that will be used for in-process analysis, release and stability testing of PT-401, which is being developed by DNAPrint Pharmaceuticals Inc., a subsidiary of DNAPrint Genomics Inc.
Ann
A recap on EPI:
http://biz.yahoo.com/iw/060314/0112989.html
Ann
Hey, usmc -
Ann
Lol, Dorsey
I do have a life...just stay up late!
Ann
Dorsey:
Glad to hear it!
A great day to you, Dorsey.
Ann
As posted by worktoplay on IV:
...Looks to me like they're beginning development of another drug, this one an EPO inhibitor. I don't know what specific neuro or cardio protective effects they anticipate, but with Sytkowski being an expert in the field, I'm certain they have something specific in mind.
R103A is a modified EPO. The "103A" stands for a substitution of Alanine for Arginine at site 103 of the molecule. It has been studied already as with application in sickle cell disease.
Here's a link to some prior work. It takes a few seconds to load but the full PDF comes up eventually:
http://www.bloodjournal.org/cgi/reprint/99/12/4400
Ann
usmc:
I left out ancestry testing. You can find a lot of info on the following web page:
http://www.genetree.com/resource/ancestryRSS.php
Take care,
Ann
usmc:
Genetree is an accredited testing laboratory & a distributor for DNAP Paternity tests.
Take care,
Ann
A function of DLS:
Defense Life Sciences, (DLSci) is dedicated to the development of commercial Life Sciences for National and Civil Defense. We bring commercial products to the Department of Defense, Department of Homeland Security, the Intelligence Community and other Federal Agencies.
Ann
Defense Life Sciences:
DNAP a client:
http://www.dlsci.com/projects.html
Ann
Eye color to determine distribution:
http://www.genetree.com/resource/eyeColorCalculator.php
Ann
DNAP Detective testing distributor:
http://www.genetree.com/other/Forensics.php
Ann
Dr. Sytkowski's credentials:
http://www.stockhouse.com/news/news.asp?tick=DNAG&newsid=3834553
Ann
Stockhldr:
"Dr. Sytkowski--I believe DNAG hired the best!"
I believe you're right!
Take care,
Ann